drugset / Trial / NCT00825721
Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract
Timeline
- Start
- 2007-11
- Primary completion
- 2009-08
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | C-KAD Ophthalmic Solution | Unknown | 1.3 % | Other |
| Comparator | C-KAD Ophthalmic Solution | Unknown | 2 % | Other |
| Comparator | C-KAD Ophthalmic Solution | Unknown | 2.6 % | Other |